Pancreatic Cancer Research

ResearcherUniversity College HospitalActive in the last 2 years

Khurum Hayat Khan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9364-6182; OpenAlex author ID A5071341853. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
64
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 7

  1. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
  2. Impact of Long-Term Chemotherapy on Outcomes in Pancreatic Ductal Adenocarcinoma: A Real-World UK Multi-Centre Study. Last author DOI 10.3390/cancers17111896↗
  3. Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm. Last author DOI 10.1016/j.ctrv.2024.102750↗
  4. The immunomodulatory role of IDO1-Kynurenine-NAD+ pathway in switching cold tumor microenvironment in PDAC. Last author DOI 10.3389/fonc.2023.1142838↗
  5. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  6. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU… Co-author DOI 10.18632/oncotarget.7208↗
  7. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. First author DOI 10.1016/j.clcc.2014.09.005↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Umair Mahmood · 2 shared papers, 2024–2025 · strength 0.61
  2. Ewa Carrier · 1 shared paper, 2024 · strength 0.36
  3. Anu R I · 1 shared paper, 2023 · strength 0.31
  4. Daniel Hochhauser · 1 shared paper, 2025 · strength 0.25
  5. Paul Miller · 1 shared paper, 2025 · strength 0.25
  6. David J. Propper · 1 shared paper, 2025 · strength 0.19
  7. Christine Hughes · 1 shared paper, 2025 · strength 0.19
  8. Fieke E. M. Froeling · 1 shared paper, 2025 · strength 0.19
  9. Debashis Sarker · 1 shared paper, 2025 · strength 0.19
  10. Claude Chelala · 1 shared paper, 2025 · strength 0.19
  11. David Kuang-Fu Chang · 1 shared paper, 2025 · strength 0.19
  12. Mairead Geraldine McNamara · 1 shared paper, 2025 · strength 0.19
  13. Hemant Mahendrakumar Kocher · 1 shared paper, 2025 · strength 0.19
  14. Pippa G. Corrie · 1 shared paper, 2025 · strength 0.19
  15. Ian Chau · 3 shared papers, 2014–2019 · strength 0.15
  16. Sing Yu Moorcraft · 2 shared papers, 2014–2019 · strength 0.10
  17. David J. Watkins · 2 shared papers, 2014–2016 · strength 0.10
  18. David Cunningham · 2 shared papers, 2014–2016 · strength 0.10
  19. Andrew H. Ko · 1 shared paper, 2019 · strength 0.06
  20. Matthew H. G. Katz · 1 shared paper, 2019 · strength 0.06
  21. Christoph Tinchon · 1 shared paper, 2019 · strength 0.06
  22. Stephen John Clarke · 1 shared paper, 2019 · strength 0.06
  23. Jaswinder Singh Samra · 1 shared paper, 2019 · strength 0.06
  24. Kyu‐pyo Kim · 1 shared paper, 2019 · strength 0.06
  25. Martin D. McCarter · 1 shared paper, 2019 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.